Fortis Healthcare Limited has informed the Exchange about Investor Presentation
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported FY25 consolidated revenue of INR 7,783 Cr, up 12.9% YoY, with operating EBITDA of INR 1,588 Cr (up 25.3%) and margin expanding 200 bps to 20.4%. Q4 FY25 revenue grew 12.4% to INR 2,007 Cr with EBITDA margin at 21.7% (vs 21.3%). Hospital business drove the growth with FY25 revenue up 14.8% to INR 6,528 Cr and margins improving to 20.5% (from 18.6%), supported by 9% ARPOB growth and occupancy rising to 69%. Diagnostics EBITDA margin (ex-one-offs) expanded to 22.0% from 19.6%. The board recommended a dividend of INR 1 per share. Key strategic moves included acquiring perpetual 'Fortis' brand rights for INR 200 Cr, consolidating Agilus stake to 89.2%, signing definitive agreements to acquire Shrimann Superspecialty Hospital in Jalandhar, and divesting the Richmond Road facility. Net debt rose to INR 1,694 Cr (0.93x EBITDA) mainly due to the Agilus stake buyout.
Positive for shareholders — strong double-digit revenue growth, healthy margin expansion, and brand ownership strengthen the company's competitive position. The increased debt from acquisitions is a watchpoint, but leverage remains modest at under 1x EBITDA. The dividend, multi-year bed expansion plan (~2,000 beds over FY26-29), and improving diagnostics margins signal continued growth momentum.